Physician

Anshul Kumar, M.D.

According to 2025 Medicare claims, Anshul Kumar, M.D. (NPI: 1558674226) practices nephrology in the Vineland, NJ market, with the plurality of this provider's patient population coming from Cumberland, NJ. This provider's primary affiliated billing organization is CUMBERLAND NEPHROLOGY ASSOCIATES (NPI: 1710956370; TIN: 223586136) and primary practice location at 08360-6516. Kumar is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Kumar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 490 traditional Medicare patients, billed 3,030 HCPCS/CPT codes, and received $264,324 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 1,572 prescription claims across 255 beneficiaries totaling $173,399 in drug costs, led by Rayaldee (Calcifediol). DME data shows 49 claims. Open Payments data shows 65 records totaling $1,200. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $75,273 and ending at $173,399. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	630	3,613	$259,719
2016	688	4,444	$292,388
2017	713	4,126	$295,304
2018	728	4,157	$320,288
2019	635	3,659	$290,606
2020	479	2,633	$216,289
2021	537	3,238	$292,584
2022	507	2,712	$273,816
2023	496	3,023	$290,762
2024	490	3,030	$264,324

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	169	1,116	$75,273
2016	207	1,379	$141,287
2017	220	1,580	$150,770
2018	225	1,627	$121,360
2019	242	1,512	$95,880
2020	239	1,485	$108,670
2021	225	1,414	$106,391
2022	245	1,414	$119,970
2023	254	1,548	$202,571
2024	255	1,572	$173,399

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	11	$207
2018	N/R	88	$5,485
2019	N/R	85	$5,991
2020	N/R	48	$3,987
2021	N/R	29	$474
2022	N/R	35	$574
2023	N/R	11	$188
2024	N/R	49	$854

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	220	294	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	114	196	$97
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	229	707	$64
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	116	299	$40
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	140	260	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rayaldee	Calcifediol	31	930	$51,459
Prosol	Parenteral Amino Acid 20% No.1	70	482	$12,811
Sevelamer Carbonate	Sevelamer Carbonate	35	1,935	$7,164
Bumetanide	Bumetanide	125	9,895	$5,513
Valsartan	Valsartan	63	5,190	$3,533

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	20	$409
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	65	$1,200	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anshul Kumar, M.D.?

Tedicare shows public-source Medicare data for Anshul Kumar, M.D. (NPI 1558674226), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anshul Kumar, M.D. have ACO affiliation data?

Anshul Kumar, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Anshul Kumar, M.D.?

Anshul Kumar, M.D. is linked to CUMBERLAND NEPHROLOGY ASSOCIATES (billing NPI 1710956370) in the available physician profile data.

Does Anshul Kumar, M.D. have Open Payments data?

Anshul Kumar, M.D. has 65 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.